Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas

Gupta, V. K.; Su, Yuzhuang S.; Samuelson, Christian G.; Liebes, Leonard; Chamberlain, Marc C.; Hofman, Florence M.; Schönthal, Axel H.; Chen, Thomas C.

doi:10.3171/jns.2007.106.3.455

Cited by 65 publications

(29 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other newer agents, such as irinotecan and temozolomide, were deemed to have the potential to prevent recurrence, but failed in recent studies. [6][7][8]10 Therefore, at this time, the use of these agents should be reserved for patients who have documented recurrence and are not surgical candidates, and whose lesion is unresponsive to radiation. Based on the findings in this study, surgery is an effective therapy, even for recurrent tumors, and should be considered an option for all patients able to undergo an operation.…”

Section: Discussionmentioning

confidence: 99%

Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas

Sughrue¹,

Sanai²,

Shangari³

et al. 2010

JNS

131

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas

Sughrue¹,

Sanai²,

Shangari³

et al. 2010

JNS

131

View full text Add to dashboard Cite

show abstract

“…6 Currently, there are no chemotherapeutic regimens that effectively treat meningiomas, but agents such as bevacizumab are being evaluated for the treatment of Grade II and III meningiomas. 4,10 Finally, hypofractionated radiosurgery delivery systems, such as the Gamma Knife Extend (Elekta Instruments AB) may expand the versatility of radiosurgical treatment and ultimately result in better outcomes for patients harboring Grade II and III meningiomas.…”

Section: The Role Of Radiosurgery For Who Grade II and Iii Meningiomasmentioning

confidence: 99%

The role of radiosurgery in the management of WHO Grade II and III intracranial meningiomas

Ding¹,

Starke²,

Hantzmon³

et al. 2013

FOC

View full text Add to dashboard Cite

Object WHO Grade II and III intracranial meningiomas are uncommon, but they portend a significantly worse prognosis than their benign Grade I counterparts. The mainstay of current management is resection to obtain cytoreduction and histological tissue diagnosis. The timing and benefit of postoperative fractionated external beam radiation therapy and stereotactic radiosurgery remain controversial. The authors review the stereotactic radiosurgery outcomes for Grade II and III meningiomas. Methods A comprehensive literature search was performed using PubMed to identify all radiosurgery series reporting the treatment outcomes for Grade II and III meningiomas. Case reports and case series involving fewer than 10 patients were excluded. Results From 1998 to 2013, 19 radiosurgery series were published in which 647 Grade II and III meningiomas were treated. Median tumor volumes were 2.2–14.6 cm3. The median margin doses were 14–21 Gy, although generally the margin doses for Grade II meningiomas were 16–20 Gy and the margin doses for Grade III meningiomas were 18–22 Gy. The median 5-year PFS was 59% for Grade II tumors and 13% for Grade III tumors, which may have been affected by patient age, prior radiation therapy, tumor volume, and radiosurgical dose and timing. The median complication rate following radiosurgery was 8%. Conclusions The current data for radiosurgery suggest that it has a role in the management of residual or recurrent Grade II and III meningiomas. However, better studies are needed to fully define this role. Due to the relatively low prevalence of these tumors, it is unlikely that prospective studies will be feasible. As such, well-designed retrospective analyses may improve our understanding of the effect of radiosurgery on tumor recurrence and patient survival and the incidence and impact of treatment-induced complications.

show abstract

“…The study of Chamberlain et al [69] on the contrary showed a limited efficacy. Contrasting results exist on the efficacy of irinotecan on preclinical studies [70].…”

Section: Chemotherapymentioning

confidence: 96%

Meningiomas’ Management: An Update of the Literature

Cossu¹,

Messerer²,

Parker³

et al. 2016

Neurooncology - Newer Developments

View full text Add to dashboard Cite

Meningiomas are the most common primary intracranial tumors in the adult population [1]. They are generally considered benign lesions but after the 2007 WHO classification, the proportion of atypical meningiomas has steeply increased. Surgery is considered the mainstay of the treatment and a complete resection is considered curative in WHO grade I meningiomas. The role of adjuvant treatments like radiotherapy (stereotactic radiosurgery or conventional external beam irradiation) and chemotherapy in more aggressive cases is still discussed, above all in WHO grade II meningiomas. We would like to expose the most important advances in meningiomas' management in accordance with the recent literature evidences.

show abstract

Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas

Cited by 65 publications

References 32 publications

Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas

Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas

The role of radiosurgery in the management of WHO Grade II and III intracranial meningiomas

Meningiomas’ Management: An Update of the Literature

Contact Info

Product

Resources

About